TROP2-targeted antibody-drug conjugates for extramammary Paget disease

BindingDB literature identifies TROP2 as a potential targeted therapy for extramammary Paget disease in a multicenter Japanese study (DOI:10.1038/s41598-024-84566-y). TROP2 is highly expressed in various epithelial cancers and represents a validated target for antibody-drug conjugates like sacituzumab govitecan, which could be repurposed for EMPD.